Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deja Vu: EGF receptors drive resistance to BRAF inhibitors.

Literature DB >> 23658295

Deja Vu: EGF receptors drive resistance to BRAF inhibitors.

Abstract

The promise of personalized medicine is upon us, and in some cancers, targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but while drugs that target BRAF and its downstream signaling pathway are effective in melanoma, they are ineffective in thyroid cancer. In this issue of Cancer Discovery, Montero-Conde and colleagues investigate why thyroid cancer is resistant to BRAF inhibitors despite the presence of BRAF mutation.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2013 PMID： 23658295 PMCID： PMC3736320 DOI： 10.1158/2159-8290.CD-13-0131

Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 39.397

13 in total

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors: Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245

2. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors: Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal: Nature Date: 2012-01-26 Impact factor: 49.962

3. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors: Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal: Cancer Discov Date: 2012-01-16 Impact factor: 39.397

4. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

Authors: Gerald S Falchook; Karl D Lewis; Jeffrey R Infante; Michael S Gordon; Nicholas J Vogelzang; Douglas J DeMarini; Peng Sun; Christopher Moy; Stephen A Szabo; Lori T Roadcap; Vijay G R Peddareddigari; Peter F Lebowitz; Ngocdiep T Le; Howard A Burris; Wells A Messersmith; Peter J O'Dwyer; Kevin B Kim; Keith Flaherty; Johanna C Bendell; Rene Gonzalez; Razelle Kurzrock; Leslie A Fecher
Journal: Lancet Oncol Date: 2012-07-16 Impact factor: 41.316

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors: Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal: Lancet Date: 2012-06-25 Impact factor: 79.321

6. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

Authors: D Neil Hayes; Amy S Lucas; Tawee Tanvetyanon; Monika K Krzyzanowska; Christine H Chung; Barbara A Murphy; Jill Gilbert; Ranee Mehra; Dominic T Moore; Arif Sheikh; Janelle Hoskins; Michele C Hayward; Ni Zhao; Wendi O'Connor; Karen E Weck; Roger B Cohen; Ezra E W Cohen
Journal: Clin Cancer Res Date: 2012-01-12 Impact factor: 12.531

7. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

Authors: Keith T Flaherty; Jeffery R Infante; Adil Daud; Rene Gonzalez; Richard F Kefford; Jeffrey Sosman; Omid Hamid; Lynn Schuchter; Jonathan Cebon; Nageatte Ibrahim; Ragini Kudchadkar; Howard A Burris; Gerald Falchook; Alain Algazi; Karl Lewis; Georgina V Long; Igor Puzanov; Peter Lebowitz; Ajay Singh; Shonda Little; Peng Sun; Alicia Allred; Daniele Ouellet; Kevin B Kim; Kiran Patel; Jeffrey Weber
Journal: N Engl J Med Date: 2012-09-29 Impact factor: 91.245

8. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

9. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

Authors: Cristina Montero-Conde; Sergio Ruiz-Llorente; Jose M Dominguez; Jeffrey A Knauf; Agnes Viale; Eric J Sherman; Mabel Ryder; Ronald A Ghossein; Neal Rosen; James A Fagin
Journal: Cancer Discov Date: 2013-01-29 Impact factor: 39.397

10. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962

13 in total

Review 1. Dabrafenib and its use in the treatment of metastatic melanoma.

Authors: Samantha Bowyer; Rebecca Lee; Alberto Fusi; Paul Lorigan
Journal: Melanoma Manag Date: 2015-08-10

Review 2. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Authors: Maria Romina Girotti; Grazia Saturno; Paul Lorigan; Richard Marais
Journal: Mol Oncol Date: 2014-08-15 Impact factor: 6.603

10. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.

Authors: Devin G Roller; Brian Capaldo; Stefan Bekiranov; Aaron J Mackey; Mark R Conaway; Emanuel F Petricoin; Daniel Gioeli; Michael J Weber
Journal: Oncotarget Date: 2016-01-19

Deja Vu: EGF receptors drive resistance to BRAF inhibitors.

1. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

2. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

3. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

4. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

6. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.

7. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

8. Inhibition of mutated, activated BRAF in metastatic melanoma.

9. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

10. Mutations of the BRAF gene in human cancer.

Review 1. Dabrafenib and its use in the treatment of metastatic melanoma.

Review 2. No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients.

Review 3. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma.

4. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.

5. Converting biology into clinical benefit: lessons learned from BRAF inhibitors.

Review 6. Targeting the Raf kinases in human cancer: the Raf dimer dilemma.

7. Antitumor effects of anlotinib in thyroid cancer.

8. Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.

Review 9. Dabrafenib for treatment of BRAF-mutant melanoma.

10. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.